370 articles
Small NIH study tests oral drug tofacitinib as potential new treatment for systemic lupus erythematosus with fewer side effects.
Small study tests whether tocilizumab can achieve faster, deeper remission in newly diagnosed rheumatoid arthritis patients.
Phase 2 trial tests novel therapy for patients who failed standard biologics and JAK inhibitors in 145-person study.
Phase 3 trial tests otilimab against standard care in 550 patients who failed previous biologics and JAK inhibitors.
Small study explores how tofacitinib may address chronic pain that persists even when inflammation is controlled in RA patients.
Researchers used blood biomarkers and machine learning to predict which expensive RA treatments work best for individual patients.
NYU study reveals how targeted immune therapy transforms inflammatory responses in rheumatoid arthritis treatment.
Small trial tests modified immune cells injected directly into chest cavity to fight aggressive cancer with 12-month survival rate.
Small trial tests innovative treatment IBI346 for blood cancer patients who didn't respond to standard therapies.
Engineered immune cells target CD19+ cancer cells in patients with treatment-resistant lymphoma and leukemia.
Modified immune cells targeting GD2 protein demonstrated safety in treating aggressive childhood cancers like neuroblastoma and osteosarcoma.
Researchers tested a new drug combination targeting immune suppression in advanced solid tumors before early termination.
